Harpoon Therapeutics, Inc. (HARP) is up 6.15% in the after-hours trading session at the price of $9.5 despite any recent news. HARP is a clinical-stage immunotherapy company that develops a novel class of T-cell engagers. They check the power of the human immune system to treat patients with cancer and other diseases.
HARP to Participate in Upcoming Virtual Investor Conferences
On 2nd September 2021, HARP published that President and Chief Executive Officer Gerald McMahon will participate in three upcoming virtual investor conferences. The first penal will be at Citi’s 16th Annual BioPharma Conference on 9th September 2021. The discussion topic is Large Molecule Drugs for Oncology – Framing Tips of the Spear for Novel Antibodies and Protein Therapeutics. The second discussion, fireside chat, will be held at Baird’s 2021 Global Healthcare Conference on 15th September 2021. The third conference will be at Cantor’s 2021 Virtual Global Healthcare Conference on 28th September 2021.
Second Quarter 2021 Financial Results and Corporate Updates
On 5th August 2021, Harpoon Therapeutics published its financial results for the second quarter ended on 30th June 2021. Chief Executive Officer of HARP Jerry McMahon remarked that the clinical data arising for their proprietary TriTAC portfolio continued to be encouraging. Their HPN424, HPN536, and HPN328 have shown cancer target engagement, significant treatment duration, and tumor size reduction. They remain focused on increasing dose levels across all four programs and providing additional interim clinical pipeline data, he added.
HARP Second Quarter 2021 Financial Results
HARP reported revenue of $5.8 million for the second quarter ended 30th June 2021. Revenue was $2.8 million for the second quarter ended on 30th June 2020. For the six months ended on 30th June 2021, revenue was $14.8 million. Revenue of $6.1 million was reported for the same six months of the previous year. The increase in revenue for the second quarter of 2020 was primarily due to higher research and development services revenue related to Harpoon’s Development and Option Agreement with AbbVie. For the second quarter of 2021, the increase in revenue was due to the delivery of the second initial target under Harpoon’s Amended and Restated Discovery Collaboration Agreement with AbbVie.
HARP reported a net loss of $16.8 million for the second quarter ended 30th June 2021. Net loss was $12.7 million for the quarter ended 30th June 2020. The net loss for the six months ended on 30th June 2021 was $78.5 million. The net loss was $25.2 million for the first six months of the previous year.
